Physician profile
Shawn Ingles
NPI 1821072901
$1,878.61
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $231 · 2020: $146 · 2021: $426 · 2022: $404 · 2023: $672.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $656 · Education: $15.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $656.49 |
| Education | $15.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $667.16 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $364.04 | 2019-2023 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $237.65 | 2019-2023 | Entyvio, Gattex |
| Celgene Corporation | $188.94 | 2021-2023 | Zeposia |
| Janssen Biotech, INC. | $158.55 | 2019-2022 | |
| Eisai INC. | $87.03 | 2023 | |
| Intercept Pharmaceuticals, INC. | $60.44 | 2022-2023 | Ocaliva |
| Nestle Healthcare Nutrition INC. | $37.45 | 2021-2022 | |
| Pfizer INC. | $29.26 | 2019 | |
| Shionogi INC | $18.31 | 2019 | |
| Braintree Laboratories, INC. | $16.21 | 2023 | Sutab, Suflave |
| Gilead Sciences, INC. | $13.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shawn Ingles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.